Cargando…

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes

INTRODUCTION: Degludec (IDeg) is an ultralong-acting insulin, with stable pharmacodynamic profile which leads to lower fluctuations in glucose levels. The effect of IDeg has not been specifically assessed in patients with unstable diabetes, defined as increased glycemic variability (GV). METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henao-Carrillo, Diana Cristina, Muñoz, Oscar M., Gómez, Ana M., Rondón, Martín, Colón, Christian, Chica, L., Rubio, Claudia, León-Vargas, Fabián, Calvachi, Maria Alejandra, Perea, Ana María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992319/ https://www.ncbi.nlm.nih.gov/pubmed/29892561 http://dx.doi.org/10.1016/j.jcte.2018.03.003

Ejemplares similares

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

The effect of Insulin Degludec on glycemic control in diabetic cats over a 12-month period
por: ODA, Hitomi, et al.
Publicado: (2020)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs
por: ODA, Hitomi, et al.
Publicado: (2018)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yang, Yunjiao, et al.
Publicado: (2022)

The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
por: Elhabashy, Safinaz Adel, et al.
Publicado: (2023)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial
por: Vrebalov Cindro, Pavle, et al.
Publicado: (2022)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
por: Kazda, Christof M., et al.
Publicado: (2023)

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
por: Zenari, Luciano, et al.
Publicado: (2020)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Insulin degludec in the first trimester of pregnancy: Report of two cases
por: Milluzzo, Agostino, et al.
Publicado: (2017)

Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series
por: Hiranput, Siwaporn, et al.
Publicado: (2018)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec
por: Takahashi, Nobuyuki, et al.
Publicado: (2016)

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
por: Tentolouris, Nikolaos, et al.
Publicado: (2019)

Clinical Factors Associated with High Glycemic Variability Defined by Coefficient of Variation in Patients with Type 2 Diabetes
por: Gómez, A M, et al.
Publicado: (2021)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
por: Mehta, Roopa, et al.
Publicado: (2020)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
por: Nosek, Leszek, et al.
Publicado: (2014)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

Pregnancy outcomes in women with type 1 diabetes using insulin degludec
por: Ringholm, Lene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r8upd91l3nov08spu9m1r4k4p5